9/16, 7:05 PM (Source: TeleTrader)
more TeleTrader news

Eli Lilly antibody drug reduces COVID hospitalizations

An experimental antibody drug that is being developed by Indianapolis-based Eli Lilly has been shown to reduce the need for hospitalizations in coronavirus patients, the company announced on Wednesday.

The drug, derived from the blood of a patient that recovered from COVID-19, was tested in a placebo-controlled trial that demonstrated its effectiveness in reducing hospitalizations when compared to a placebo.

However, the interim results have not yet been published in detail and would need to independently reviewed before making a decision whether to authorize the therapy for emergency use. Speaking to the Wall Street Journal, Eli Lilly's Chief Scientific Officer Daniel Skovronsky said the study results are "proof of concept that show an antibody against the virus can neutralize the virus in patients, which can have a beneficial effect on symptoms and hospitalizations."

Breaking the News / JC